Literature DB >> 1711903

Polymeric contrast agents for magnetic resonance imaging: synthesis and characterization of gadolinium diethylenetriaminepentaacetic acid conjugated to polysaccharides.

F E Armitage1, D E Richardson, K C Li.   

Abstract

The synthesis and characterization of polysaccharides esterified with gadolinium diethylenetriaminepentaacetic acid (GdDTPA) are described. The results of several synthetic methods are presented for esterification of dextrans and inulin with DTPA. One method results in highly conjugated products labeled with an average of 0.4 mol of GdDTPA/mol of glucopyranose unit in dextrans of up to 70,800 average molecular weight and 0.5 mol of GdDTPA/mol of fructofuranose unit in inulin. Chromatographic and potentiometric evidence supporting the absence of significant chelate cross-linking of the conjugated polysaccharides is presented. The thermodynamic stability constant, log K (Gd3+ + L4(-)----GdL-), of the complexes was 18.0 +/- 0.2 based on an independent chelate model. In vitro ester hydrolysis of the GdDTPA-dextran 70,800 (at 37 degrees C, pH = 7.4 phosphate buffer) occurs with a half-life of 21 h. The agents exhibit T1 relaxivities ranging from 1.5 to 2.3 times that of GdDTPA at 100 MHz, and decreasing in vitro relaxivity with increasing molecular weight of the dextran carrier was observed. Phantom MRI studies indicate that the T1 and T2 effects of the complexes differ from those of GdDTPA, with the polysaccharide-bound complexes exhibiting a considerably faster drop in relative signal intensity with increased concentration in T1 and T2 weighted pulse sequences.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1711903     DOI: 10.1021/bc00006a001

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  9 in total

1.  Strategies for the preparation of bifunctional gadolinium(III) chelators.

Authors:  Luca Frullano; Peter Caravan
Journal:  Curr Org Synth       Date:  2011-08-01       Impact factor: 1.975

Review 2.  Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.

Authors:  Aaron Joseph L Villaraza; Ambika Bumb; Martin W Brechbiel
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

3.  Interaction of Biphenyl-Functionalized Eu(2+)-Containing Cryptate with Albumin: Implications to Contrast Agents in Magnetic Resonance Imaging.

Authors:  Joel Garcia; Matthew J Allen
Journal:  Inorganica Chim Acta       Date:  2012-07-20       Impact factor: 2.545

4.  Eu(II)-containing cryptates as contrast agents for ultra-high field strength magnetic resonance imaging.

Authors:  Joel Garcia; Jaladhar Neelavalli; E Mark Haacke; Matthew J Allen
Journal:  Chem Commun (Camb)       Date:  2011-11-02       Impact factor: 6.222

5.  Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA).

Authors:  P Brugières; A Gaston; H R Degryse; P M Parizel; A M de Schepper; I Berry; C Manelfe; F Le Bras; C Marsault; W Wichmann
Journal:  Neuroradiology       Date:  1994       Impact factor: 2.804

6.  Contrast-enhanced fat saturation magnetic resonance imaging for studying the pathophysiology of osteonecrosis of the hips.

Authors:  K C Li; P Hiette
Journal:  Skeletal Radiol       Date:  1992       Impact factor: 2.199

Review 7.  Gadolinium-based contrast agents for magnetic resonance cancer imaging.

Authors:  Zhuxian Zhou; Zheng-Rong Lu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2012-10-09

Review 8.  In vivo molecular imaging of vascular stress.

Authors:  Marius C Wick; Christian Kremser; Stefan Frischauf; Georg Wick
Journal:  Cell Stress Chaperones       Date:  2008-05-09       Impact factor: 3.667

9.  Macromolecular Imaging Agents Containing Lanthanides: Can Conceptual Promise Lead to Clinical Potential?

Authors:  Joshua Bryson; Jeffrey W Reineke; Theresa M Reineke
Journal:  Macromolecules       Date:  2012-11-13       Impact factor: 5.985

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.